Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are absolutely right on this. I think spoofing is just a bait for the 8 accused MMs and so far they seem to have been hooked up -- wrangling around desperately, because spoofing surely will be readily proved and the MMs will definitely pay for it.
But how munch is the next question. Because I am 100% sure they have been much deep in manipulation as you suggested, ie, naked shorting for years, they must pay unprecedented sums of money, in billion if not billions to settle, because they would not prefer discovery going forward, which will lead to exposure of their whole dirty laundry in the public eye, which will lead to criminal cases against them from multiple angles, including the government.
We will just have to wait for this to comes to fruition. Buy, add, and hold.
I don't pay much attention to anything such as Advent/CRL job posting, extremely upbeat management mood, or how much is the revenue from special program, or nobody knows the direction, or other peripherals (not that they are not signs), but this:
1) JAMA Oncology paper is good; 2) patent portfolio is expanding; 3) GBM sphere is exciting and expecting approval; 4) the day before loan is good (yes it could be better as bears so conveniently criticized); 5) to be determined, and of course 6) the recent price movement in tandem with the souring general market sentiment is negative. As a result, nwbo is once again a strong.
I don't know anyone else but I pretty much think I do know the direction moving forward (not a genius to know exact timing though): MIA, MAA/BLA, regulatory approvals one after another, all will come (partnership deals if materialized are just bonus).
We will beat the general market, not by 50%, but 1,000% in not a distant future (hi Linda).
Buy, add and hold.
There are always selling and buying which makes the market setting aside the manipulation just for now.
When prices were in teens there were sellers and buyers. I am one of those who bought in that range.
Yesterday's loan in and of itself is a good deal unless you count a good deal as interest free or free money. I understand some language such as the preparation for an application for market approval sounds stupid: how come Linda Powers has not done this? But we are investing in NWBO, we got know now how it behaves that only thing we should know is this: regardless of how slow Linda moves things, at end she has always got it done.
Bearing that in mind, regardless of time, days or months. MIA approval is coming, MAA/BLA is coming ...
We may not realize this is that moment once again as we didn't realize the moment when we bought shares around teens.
At least when we bought at teens, we didn't know the data would be positive. Now we know it is positive, and regulatory bodies get to approve it, if we can put the time stamp aside just for the sake of sanity.
Buy, add, hold, be happy!
Got more filled below $0.64, feel we will be green this afternoon as general market deepens into red. Yesterday's loan alone should increase price a bit, nothing to be worry about, Linda is a human being, she moves things as most of us do.
@Arhdan9
$NWBO $XBI #CitadelScandal
Simply report: added 36k shares between $0.65-0.64 so far this morning. said too much on the bright future of #DCVax in treating all kinds of cancers alone or in combination to substantially improve OS or cure cancers. Relax, take advantage, happy!
More to come this afternoon as I has bits set below $0.64.
[as I am typing, notice some get filled already]
Watch me buy 38k shares starting from 13pm. Guess which blocks are mine until 16pm.
these shares when done are just for fun, even my shares counts would again peak.
Linda take your path and pace and a break or two when needed, I like it.
Let nothing unchecked please.
Re lawsuit, re price, re nwbo:
Just a food for thought -- It may be a possibility for the MMs to intentionally maintain the price in this range $0.70s because if they let the price rise substantially, they may fear the motive for their spoofing action may be readily established, which Citadel has vehemently try to say otherwise, despite that it just doesn't matter spoofing is spoofing regardless price increase, decrease or not.
So in that case it should be easy to collect more evidences of other kinds of illegal MM transaction activities so they do face the possibility of being exposed with more illegal activities while trying to cover one illegal activity (spoofing).
Anyhow it seems the lawsuit will enter the next phase where there will be a rich discovery of some more serious illegal activities committed by MMs during the same period, including naked shorting if a rich out-of-court deal in the billion(s) is not reached. I guess the only thing that matter to them as of now is just delay this process at any cost.
So if with news, price doesn't increase duly, Mr. Black and our lawyers should have some rewarding and exciting field days.
NWBO at this time doesn't need any forms of pumping, or any stripes of pumpers, because the JAMA Oncology paper is the testimony for that, nothing will be better than that, and today's top pick of the DCVax-L JAMA Oncology paper by American Academy of Neurology Neurology Today Editorial Board as "The News That Mattered in 2022"? is again the testimony for that, yes nothing will be better than that!
Instead, the persistent empty, repetitive, useless, soulless chatter in message board and social media by those who claim they have never taken a position of any forms, and now a new crop of deniers coming on board all of a sudden with the same empty, repetitive, useless, soulless chatter as NWBO enters a new phase toward regulatory approvals is also the testimony for that, NWBO's success indeed has also drawn increasing attention from those deniers and manipulators.
Then, perhaps the only counter-argument sort of some substance is why the price is so low because all the empty, repetitive, useless, soulless chatter is just garbage in and garbage out, deserved nothing of consideration.
As the awareness picks up while the effect of lawsuit on the manipulators continually settles in, and most importantly as this phase of regulatory approvals moves forward to a certain point, the nerve of the deniers and manipulators will break. Then, the price will go up where it deserves.
Besides making money or living, how to do it is also important for a conscious human being, often a difference between humans and animals.
You don't get the point. I am talking about a competent person who can persuade major media outlets, even the FOX,which in your word with some truth though had been taken advantage of, to come onboard reporting the breakthrough results of Northwest Bio.
The person would present them the JAMA Oncology paper;
Would precisely explain how pseudo-progression changes the primary endpoint from PFS to OS, as a result it prolongs the trial duration;
Also because of the FDA's mandate for crossover, SAP must be revised and ECA would be used in comparison;
The trial results are indeed as JAMA Oncology reported positive with clinically meaningful and statistically significant results for nGBM, a significant improvement for 17 years, and for rGBM, an even more significant improvement for over 20 years; and
The implication of the positive trial results now for GBM is broad and huge for the vaccine can potentially be used to treat all solid tumors, and can be an essential part of cure for many cancers in combination.
After that I think the media would understand better Northwest Bio's stance, and I don't think even FOX would feel it would loss face if it follows up and reports the final results of the trial it reported before. And some of them may feel if not report now, it would miss out truly a breaking news with huge positive implication for years to come.
At the time, Northwest Bio was still a Nasdaq traded company. And Les was saying the vaccine would be available in late 2014. LOL
I guess part of the reason FOX has not followed up as promised is Northwest Bio's huge miss on its timeline.
But we all know the story why, and I think if the Northwest Bio has somebody competent enough, it should not be very difficult to explain why.
why PFS > OS
As a result the trial takes longer than anticipated.
You may be right the major cable channels won't touch a stock on the OTC, but the channels can of course report on major medical and biotech breaking news. They can and should report major advances in clinical trials and potential new treatments which have the potentials to save lives regardless what company which hold the news!
It's just a matter of who can do that job, contacting and persuading the media if they don't report the news, they are missing out a major breaking news.
That means they may not have interests or may be prohibit to reporting an OTC company but they should be able to report substance news. It will be no taboo for them to report the results of the Phase 3 clinical trial using DCVax-L (Murcidencel) vaccine to treat GBM patients.
The problem is does Northwest Bio have the right advocating firm/person to do that kind of job? From the history, Northwest Bio seems to have never had that kind of record. Can this time be different with the positive news and JAMA publication?
Personally, I think it is coming!
28k shares more this morning so far, steadily averaged up my base. People want to buy high at assuring time such as with good news, not me. I like to buy at pessimistic times.
Look at the huge payday ahead, not a problem for me, either it's months, days or year.
MIA, BLAs to multiple RAs, deals of any kind but substantial, market awareness picking up, VIPs with big $ onboard, RA approval.
Dynamic of current pessimism can change anytime with news either expected or unexpected.
For a long time, I have advocated for no transparency or minimal transparency allowed by the law. I don't care about temporary "darkness" but I do care to get shorts burned while making multiple millions of profit.
Added 30k shares today at $0.729 to average up my cost base. Never pay attention to day to day price move except when I want to buy shares. Even with well over 7-figure of shares I am holding, no intention to trade a single share despite knowing MIA is imminent, when it happens price would be up, and BLA submissions to multiple RAs soon follow, again price would be up. Look at the first RA approval in 6-8 months.
If price continue to be at this low or lower, intended to buy more to average up. The general market sucks which puts pressure on our price, but this stock needs only a single big positive thing to say bye bye to low price.
Increased awareness, a solid institution taking a significant slice, regulatory news, lawsuit yielding material news, hints of big P knocking the door, ...
Then it will change all trading dynamic and find a strong support!
Yes indeed, I have more example attached later one in the same post which shows it can happen either days apart or at the same day, or just one day apart. Done my digging, I think it's enough.
More examples:
UK MIA 20075 ACCORD HEALTHCARE LIMITED ACCORD HEALTHCARE LIMITED, GROUND FLOOR, SAGE HOUSE, 319 PINNER ROAD, HARROW, HA1 4HF, UNITED KINGDOM ACCORD HEALTHCARE LIMITED, EDGEFIELD AVENUE, NEWCASTLE UPON TYNE, NE3 3NB, UNITED KINGDOM
Human 25/11/2022
UK MIA(IMP) 20075 ACCORD HEALTHCARE LIMITED ACCORD HEALTHCARE LIMITED, GROUND FLOOR, SAGE HOUSE, 319 PINNER ROAD, HARROW, HA1 4HF, UNITED KINGDOM ACCORD HEALTHCARE LIMITED, EDGEFIELD AVENUE, NEWCASTLE UPON TYNE, NE3 3NB, UNITED KINGDOM
Investigational 25/11/2022
This one days apart:
UK MIA(IMP) 19054 ALIUM MEDICAL LIMITED ALIUM MEDICAL LIMITED, UNIT 7, CAPITAL BUSINESS PARK, MANOR WAY, BOREHAMWOOD, WD6 1GW, UNITED KINGDOM Investigational 13/07/2022
UK MIA(IMP) 17087 ALLERGY THERAPEUTICS (UK) LIMITED ALLERGY THERAPEUTICS (UK) LIMITED, DOMINION WAY, WORTHING, BN14 8SA, UNITED KINGDOM ALLERGY THERAPEUTICS 2, UNIT A/B, DOMINION WAY, WORTHING, BN14 8NW, UNITED KINGDOM
Investigational 29/09/2022
UK MIA 17087 ALLERGY THERAPEUTICS (UK) LIMITED ALLERGY THERAPEUTICS 2, UNIT A/B, DOMINION WAY, WORTHING, BN14 8NW, UNITED KINGDOM ALLERGY THERAPEUTICS (UK) LIMITED, DOMINION WAY, WORTHING, BN14 8SA, UNITED KINGDOM
Human 06/10/2022
the one below, one day apart:
UK MIA(IMP) 22443 ALLIANCE MEDICAL RADIOPHARMACY LIMITED ALLIANCE MEDICAL RADIOPHARMACY LIMITED , ROYAL MARSDEN HOSPITAL, DOWNS ROAD, SUTTON, SM2 5PT, UNITED KINGDOM
Investigational 11/07/2022
UK MIA 22443 ALLIANCE MEDICAL RADIOPHARMACY LIMITED ALLIANCE MEDICAL RADIOPHARMACY LIMITED , KEELE UNIVERSITY SCIENCE PARK, KEELE, ST5 5BX, UNITED KINGDOM ALLIANCE MEDICAL RADIOPHARMACY LIMITED , ROYAL PRESTON HOSPITAL, SHAROE GREEN LANE, FULWOOD, PRESTON, PR2 9HT, UNITED KINGDOM ALLIANCE MEDICAL RADIOPHARMACY LIMITED , ROYAL MARSDEN HOSPITAL, DOWNS ROAD, SUTTON, SM2 5PT, UNITED KINGDOM
ALLIANCE MEDICAL RADIOPHARMACY LIMITED, UNIT 19, QUADRUM PARK, OLD PORTSMOUTH ROAD, PEASMARSH, GUILDFORD, GU3 1LU, UNITED KINGDOM
ALLIANCE MEDICAL RADIOPHARMACY LIMITED, NOBEL WAY, DINNINGTON, SHEFFIELD, S25 3QB, UNITED KINGDOM
Human 12/07/2022
And most interesting thing, as I have suspected for NWBO as well, MIA(IMP) and MIA can be issued on the same day (an example below) or days apart (I have suspected we will have MIA issued in days):
UK MIA(IMP) 50506 RECIPHARM HC LIMITED RECIPHARM HC LIMITED, LONDON ROAD, HOLMES CHAPEL, CREWE, CW4 8BE, UNITED KINGDOM
Investigational 24/12/2021
UK MIA 50506 RECIPHARM HC LIMITED RECIPHARM HC LIMITED, LONDON ROAD, HOLMES CHAPEL, CREWE, CW4 8BE, UNITED KINGDOM
Human 24/12/2021
It is definitely not the same thing or just an extension of the previously issued authorization (https://www.otcmarkets.com/stock/NWBO/news/Northwest-Biotherapeutics-Announces-Filing-of-Application-for-License-for-Commercial-Manufacturing-at-Sawston-UK-Facilit?id=363861)
December last year's pr: "The second and third licenses were received in December, 2021, from MHRA, and provided authorization for manufacturing cellular therapies for use in clinical trials and compassionate use ("Specials") cases, respectively."
My guess is it's the real deal, even if not the final issuance, but it signifies all parts have been inspected and all outstanding items have been resolved.
So maybe this is it or a final issuance may be just days away. We will know something definite tomorrow as many investors have contacted the company for clarification.
Definitely tomorrow morning .
At this stage without any approved products such as approved DCVax-L, it's of course on the legal basis of INVESTIGATIONAL (clinical trials), ie MIA (IMP). The significance for this is that all parts have been checked ok for finally commercial manufacturing authorization issuance pending product approval.
Once after MHRA reviews BLA, the MIA (IMP) wold change to MIA on the legal basis of HUMAN.
So IMO this is what we should get at this stage, and it's as significant as a commercial manufacturing license pending approval of a manufacturing product.
The authorization for investigational manufacturing had been issued last year on 21 December: https://nwbio.com/northwest-biotherapeutics-announces-mhra-approval-of-license-for-gmp-manufacturing-at-sawston-uk-facility/
No need for MHRA to authorize the same thing twice, although with different forms.
Nobody would be trustworthy posting in a bb of forecasting materially significant news with dumb confidence. It's elementary reasoning. Of course sometimes a dead clock is right twice a day.
Dr. Brem's rebukes to AF's ignorant tweet re early state $MRNA $MRK combo trial:
Contrast today’s $MRNA $MRK encouraging mRNA neoantigen cancer vax news with the futility of the $NWBO “dumb” dendritic cell technology. I don’t expect $NWBO ‘s odious, online mob to understand why they’re being sold bupkis. pic.twitter.com/n9abXqDmDi
— Adam Feuerstein ✡️ (@adamfeuerstein) December 13, 2022
Preemptively bought 30k shares more this morning. The reason is because I knew someone would ploy manipulation based on mrna+merck early stage combo trial + AF's dumb tweet. My response besides the above, here
$NWBO $XBI @adamfeuerstein talking about early stage data not peer reviewed. for an already immune compromised patient,not enough cells to use even immune response triggered; deadly cytokine storm, a treatment no one can afford. DCVax overcomes all above shortcoming! pic.twitter.com/FNb2vjYPP4
— Arh Dan (@Arhdan9) December 13, 2022
Just bought 15k more at around 0.84, since I bought i went up and {ok it down a bit at 9:45, I shall do more then}. If we all buy some, $1 is just some keys away.
As I said too many traders, pawns of MMs, short hedges in this board. So this is my last post, and I am back to my holidays on this board.
Agree. on the other hand, this stock has too many traders in addition to committed shorts, MMs, AF, etc., but lack of committed longs, particularly the big ones. the few hedges with positions are either not big enough or not committed, so basically they don't count in my calculation.
This has continually presented a hugely undervalued price for those who aim big future return.
As I am typing this, the price looks very attractive for me. I am going to back to hit buy key.
GL
Approvals are in the card, nothing has changed. Even old school Stupp agrees (he doesn't imply he disagree anyway). Anyone who may question like Stupp whether efficacy of DCVax-L for nGBM is derived from biases or some kind of accident, or something else but DCVax-L, just ask this simple question: if the efficacy not from DCVax-L, why the same DCVax-L in the same trial for the same patient population has produced this resounding, hugely positive OS improvement for rGBM patients?
It would be an elementary reasoning, and the conclusion is yes the efficacy seen for nGBM in the trial is indeed from DCVax-L, and it's impossible from anything other that!
Added 30k shares yesterday to my well over 7-figure existing shares after carefully comprehend Stupp's commantary. I don't know how price will be today or on the days ahead, I do know it's vastly undervalued in the long run. Intended to buy more when price is still in such ranges.
Soft bash commentary wrangling on some already well-explained yet understandably not perfect issues. Considering the high stake of DCVax platform when approved on his "enterprise" Stupp protocol and TT Fields (Tumor Treating Fields), yes he intended to ignore/downplay the pristine safety profile and the efficacy evidence resulted from unprecedented efficacy on rGBM patients. I bought 30k shares more today after a while of hesitation after reading his commentary.
BTW, below is my email to him sent this morning:
On your commentary titled "2022 Top Story in Oncology: DCVax in Patients With Newly Diagnosed and Recurrent Glioblastoma"
Yahoo/Sent
Xxx xxx@yahoo.com>
To:roger.stupp@northwestern.edu
Thu, Dec 8 at 1:22 p.m.
Dear Dr. Stupp,
Well first thank you very much for your significant, unmatched contribution to GBM treatment and management over the past decades. Do you think what is important and significant in terms of DCVax-L treatment for GBM patients, besides what you having reasoned and questioned, is its benign safety profile, the strong support of its efficacy from the trial results obtained for rGBM patients? Your suggestion for its full potential with other approved agents in combination is duly appreciated.
Looking forward to your reply,
Sincerely,
xxx, PhD
I inquired and was also offered C shares; then my wife came up with a better idea: since our family has already owned too many shares, and the C shares we planned to buy would still be a small faction so our decision was instead to buy in the open market taking the advantage of low share price (250k shares bought so far).
The reason is that by buying in the open market we hoped the next offered price for C shares would be higher than the previous offering of roughly about $0.62 per share ($15-16/25). We hate to see share price constantly got negative impact with each offering, which has happened previously.
The more investors buy shares from open market the chance is higher the next offering would be at higher price.
The above is exactly the reason I told Les about our decision.
Because the vast majority of crossovers are composed of mesenchymal GBM while treatment arm consists of much much less mesenchymal GBM.
If you are interested, you should compare OS of mesenchymal GBMs between the crossovers and the treatment.
Contrary to SOC or other treatments where mesenchymal GBMs are the worst group in terms of OS, in our DCVax-L trial, patients with mesenchymal GBMs have experienced the best OS outcomes, regardless the arms.
Thank you eagle8. That's my understanding in a strategic level. In terms of tactical level, I do think contrary to the mood of the board or the sign shown from reading the share price movement since after 10 May presentation (short attack), we are actually golden if one holds, or more than golden if one continually adds shares at this price range:
The bear are mostly opportunists who have taken advantage of no imminent breaking news since the company is observing a quiet period, either because of journal embargo or more realistically regulatory negotiation. But, they have been highly in debt of shares, indicated by unprecedentedly high volumes of shares deemed fail to deliver, and this part is only a tip in the iceberg if naked shorts are considered.
And news although most may think it's not imminent, who knows when?
The long have been endured hardship and now have been seasoned. Faced with the same situation of vacuum of news/update/next steps, etc., we are holding our shares at close to years' low end, meaning the bear have equivalently loaded with either borrowed shares or naked shorted shares in an unprecedented level.
Despite short-term doom injected by defenselessness quietness, the long-term prospect is bright, even the short know DCVax-L will get some kind of regulatory approval, if not a widespread approval and newly adopted standard of care most long and average persons believe after digesting the great trial data released at NYAS on 10 May that both the primary and secondary endpoints are met statistically significantly.
So who should have a good sleep? Are those who have been heavily in debt of shares or those who have held and continually add shares?
Like FED has been forced its hand to resort to hawkish stand to raise interest rates, MMs will be in a short while forced to buy back shares, let alone the usual naked shorted wolfpack who are doomed.
If you add shares today, you are not brave, you are smart!
GL
To the board: Think a bit more rationally out of box. We are much more than whether or when a publication of trial results will come or in which prestigious journal will the results be published, because that's not the point.
Making no mistake, the results will be published in a first-tier medical journal. If you have not realized this, you cannot be taught!
There is definitely something more than just a publication, and of course it's the approval of RAs, particularly FDA. To that end, Linda has put the whole management team into an endless quiet period, and when things are settled, it may show it's an indeed a wise decision for all parties involved.
So "forget" publication because it's a convenient and strategic thing up to this point.
So it's absolutely possible a RA approval may come earlier than the publication, or come simultaneously or a short time spaced.
The most important thing which the company has pursued so far is regulatory whisper.
$NWBO $XBI @POTUS
— Arh Dan (@Arhdan9) June 7, 2022
Refreshed FDA whispers: here you go #NWBO #GBM #immunotherapy #endcancer #moonshot #innovation #reincarnation #humanity. Boom you go $NWBO - my humble understanding of the current and near future status. Ignore negativity! All will come into place in due time! pic.twitter.com/SHUxPpTQFZ
Instead of useless debates and dispositions, save your time and others reading the following and then think hard (never stressed enough unfortunately).
Benefit-Risk Assessment in Drug Regulatory Decision-Making
Benefit-risk assessment is the foundation for FDA's regulatory review of human drugs and biologics.4 In. PDUFA V, FDA's Center for Drug ..
https://www.fda.gov/files/about%20fda/published/Benefit-Risk-Assessment-in-Drug-Regulatory-Decision-Making.pdf
When it comes to FDA approval, the simple question is "does the drug/biologic product's benefits outweigh its risks?" Please applies this to NWBO DCVax-L approval for #GBM.
Although not approved yet, the headline today re Novavax Vaccine expert opinion should fill the emptiness caused by doubts and uncertainty re NWBO.
FDA Advisors Say Novavax Vaccine’s Benefits Outweigh Its Risks, Clearing Way for Authorization
Last Updated: June 7, 2022 at 3:46 p.m. ET
First Published: June 7, 2022 at 8:01 a.m. ET
Does the benefits of DCVax-L for GBM outweigh the risks?
It's exciting news but first you have to put thing in perspective: for this kind of cancer (localized, not yet spread) 5-year survival rate is more than 90%, and the trial has now only followed these small number of patients up to 25 months.
It's still a long road to go to see if the exciting results today can hold.
But good for them, congrats!
[Compare that to the prognosis of GBM, you know the story. Cheer]
AF and the statnews are about nothing they have ever claimed to be as journalist and a premier health news outlet, but all about finding the niche to profit, which is cheer leading for big pharmaceutical companies while on the same purpose bashing and destroying small biotech companies which are a threat to big Ps, so that the big Ps can either operate their business as usual or scoop the innovative small biotech companies pennies on the dollar.
So really nothing about the truth, or the whole picture, the common sense, but all about footing for their bosses, the big Ps, in anyway allowed or not allowed by the law.
This is not a structure with written specifications or binding documents, but their modus operandi.
So really only thing can withhold them is conscience. In the case of AF, nothing can withhold him, for he has no conscience at all.
Again unbelievably naive opinion/observation from a pro. Ever heard the term Naked Shorting?
If the debate whether there is naked shorting whatever in the Great United States of America stock market, or in particularly has there been significant naked shorting ongoing against the tiny biotech nwbo may have some warrant after the maddening downfall of price from +$12 to mere $0.14 on suspected false trial fail narrative and before 10 May 2022, the eventful day when the suspected naked shorting footing AF again was "re-glorified" with the participation of all MMs that anyone can easily name them, with price dropped a whopping 78% on that single day alone on the backdrop of in effect the presentation of very good trial results at NYSA.
Not a single or several and in effect any funds/persons would buy a stock like a drunken sailor and then sold all in a single day as if the earth would no longer exist tomorrow. None, if not for one purpose and the only purpose which is to drive the company to bankrupt or practically for our case today to force the company to become a bottom fishing stock for acquirer(s).
Sound depressed, yes if you are a swing trader, but no one is a long-term holder. The evil force will let it go. They have no choice. Data is out, Not everyone is dumb enough to understand what these data sets as whole mean in terms of RA approval.
That eventful day and the trading after that day indicate the naked short wolfpack is indeed alive and well in our land, they will serve us well when time is come.
Those MMs actually are very funny. You cannot get the shares you want when there are no shares available. It's better to get it below $2 instead much higher.
Those money making machine (algo) will learn one thing or two soon.
Implication? Safety, safety and safety!
cart-t which Statnews has been pumping is dangerous while DCVax-l, autologous dendritic cells pulsed with tumour lysate antigen is very safe as shown by data presented at NYAS on 10 May.
Next and the last check is whether it is also efficacious and the answer is also yes. So it's unfathomable why FDA will not approve on its own ground of benefit-risk assessment.
The market is now in a shitty situation. Most development stage biotech companies have been traded below their cash value. In this sense, we are relatively faring well.
Thing may change if ......
yea it's the low expectation and the fact that Linda and the gang have so far failed to actively and positively engage the market that may in effect this time get into it after they climb out of the embargo hole.
I don't hold my breath either, but even a tortoise will eventually get there.
Arh Dan
@Arhdan9·
2h
$NWBO $XBI @ASCO
#ASCO
Still a bit doubt w/ the primary endpoint OS for nGBM met w/ p-value <0.002, then the doubt will be cast aside that the secondary endpoint OS for rGBM also met w/ even more significant separation & p-value <0.001. RAs will approve DCVax on their own ground:
https://twitter.com/Arhdan9/with_replies
Not necessarily. SP can change drastically and the uptrend can sustain if
1) one or two major funds take significant position, something around 1% of the float, and because of their sizes, willing to absorb any short selling, naked or not, thereby at least maintain the steadiness of sp. After that the market will take care of it for continued appreciation uptrend, and/or
2) Any definite sign of RA approval. We long-term investors or investors who have done enough DD all know UK is in that position to approve, but the market doesn't know which is waiting for a definite sign, like a pr, and/or
3) Any definite sign/pr indicates FDA is onboard with SAP, endpoints, or the company can reveal some positive discussion with FDA re BLA application with positive comments, and/or
4) A huge push-back the notion that the trial data is not adequate for FDA approval by advocacy groups which are already happening, oncologists, regulatory experts, especially after publication.
5) Miraculously, the naked short cabal is disbanded, or their footing AF is indicted with manipulation via distorted reporting, misinformation, etc.
As I hate to say, but yes it could be any day or days for a major shift and dynamic sea change.
TAs are useless shits in high alpha and beta biotech companies particularly NWBO. Now with preliminary data out to the public (NYAS presentation), only thing that matters in terms of stock price/trend is where are the buyers and where are the sellers.
This is a battle between light and darkness. Linda and the gang should now have had the upper hand with both primary and secondary endpoints being met statistically significantly, and the expectation of more encouraging data when the publication comes out.
It's really a puzzle with such beautiful data that Linda, Les, Dave have so far failed to locate and secure a significant somebody who has the resources to get in big, withstand and thwart any future naked short shitty actions. Have expressed my displeasure to the company but they seem as if they didn't know how to do it!
Linda, Les, and Dave should all be focused on this one single most important thing. Get out the comfort zone and get somebody big onboard.
Forget the BiggerC, or island boy clubs or the like. they are either too convenience-oriented or small to do something really meaningful.
So I am patiently waiting, even Linda, Les and Dave continually fail in this endeavor, I believe somebody big will find us, and the light will shine while darkness will fade away!
AF knew endpoints of DCVax-L trial had been changed from PFS to OS long before his distorted misleading article, in both the US and EU. He has had absolutely no basis for his distorted 10 May article.
The presentation is full of data, nobody would pick just a historical part (PFS data) and ignore the vast majority of data.
The objective view/analysis should look at whether the data shows DCVax-L is working or is efficacious from all data presented as a whole.
So AF is as usual a disgusting hitman.
On today's smithonstocks article: generally an insightful and plausible rebuttal to AF's said scandalous, distorted, misled article.
Although smith wrongly cited clinicaltrial.gov as source for OS primary and secondary endpoint at the time, Smith's point is still intact because AF had for several occasions openly acknowledged and attacked that Northwest Bio has updated the trial endpoints in both eu and us via tweets well before 10 May 2022 when his said article was published.
As Smith suggests it may be much useful to write to AF's superiors to demand retraction of the misleading article, fire AF, and apologize, which I agree and have done so, than just hang on in this board "complaining or pumping."
We are 35,000 investors strong, if we are united even by 10%, we can do a lot of wonderful things!